When was Gossamer Bio founded?

Gossamer Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Gossamer Bio located?

Gossamer Bio is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Gossamer Bio have?

As of Sep 30, 2026, the latest employee count at Gossamer Bio is 129.

Is Gossamer Bio a funded company?

Gossamer Bio is a funded company, having raised a total of $330M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 04, 2018.

When was the latest funding round of Gossamer Bio?

Gossamer Bio's latest funding was a $***** Post IPO round on Jul 20, 2023, with participation from 0 investor.

Where does Gossamer Bio rank among its competitors?

Gossamer Bio ranks 4th amongst 23 active competitors, of which 4 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Tenax Therapeutics, which secured $25M in Mar, 2025.

Who are the top competitors of Gossamer Bio?

Gossamer Bio's top competitors include Liquidia, Actelion and Vivus. Among them, Tenax Therapeutics secured the most recent funding round in March, 2025.

Gossamer Bio - 2026 Company Profile, Funding, Competitors & Financials

Gossamer Bio is a public company based in San Diego (United States), founded in 2017. It operates as a Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer. Gossamer Bio has raised $330M in funding from investors like Arch Venture Partners, Omega Funds and Hillhouse. The company has 23 active competitors, including 4 funded and 8 that have exited. Its top competitors include companies like Liquidia, Actelion and Vivus.

Company Details

Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer. The company has developed a drug candidate GB001 (undisclosed target), used for treating inflammatory disorders. The company has also developed first-in-class HIF-1α stabilizers for the treatment of inflammatory bowel diseases.

Website: www.gossamerbio.com/
Social
Phone Number: +1 **********
Registered Address: San Diego, California

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Public

Total Funding

$330M in 4 rounds

Latest Funding Round

Post IPO, Jul 20, 2023, $*****

Investors

Arch Venture Partners & 16 more

Ranked

4^th among 23 active competitors

Employee Count

129 as on Sep 30, 2026

Investment & Acquisitions

Respira Therapeutics

Similar Companies

Liquidia & 24 more

Exit Details

Public

View Gossamer Bio's full profile

Gossamer Bio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GOSSAMER BIO SERVICES, INC. CIN: 824677292 , United States, Active	Dec 26, 999	-	119 (As on Dec 31, 2024)	-
GOSSAMER BIO, INC. CIN: 475461709 , United States, Active	Dec 31, 2016	-	102 (As on Dec 31, 2018)	-

Gossamer Bio got listed on Feb 08, 2019.

Click here to take a look at Gossamer Bio's IPO in detail

Gossamer Bio has raised a total funding of $330M over 4 rounds. Its first funding round was on Jan 04, 2018. Gossamer Bio has 17 institutional investors.

Here is the list of recent funding rounds of Gossamer Bio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 20, 2023	4241856	Post IPO	4450043	6530621	8152239	1102868
Jul 13, 2022	1161792	Post IPO	5717301	5831400	6847995	EcoR1 & 6 more
Jul 23, 2018	6266986	Series B	7516170	2778379	Hillhouse	Invus & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Gossamer Bio's funding rounds and investors

Gossamer Bio's employee count trend

Gossamer Bio has 129 employees as of Sep 26. Here is Gossamer Bio's employee count trend over the years:

Uncover Gossamer Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gossamer Bio include Liquidia, Actelion and Vivus. Here is the list of Top 10 competitors of Gossamer Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Liquidia 2004, Morrisville (United States), Public	Developer of therapeutics for pulmonary hypertension and cardiopulmonary conditions	$90.3M	Morningside, Canaan & 18 others	68/100
2nd	Actelion 1997, Allschwil (Switzerland), Acquired	Discovery, development, and commercialization of innovative treatments for orphan diseases	$46M	Atlas Venture, NeoMed & 11 others	63/100
3rd	Vivus 1991, Mountain View (United States), Public	Developer of therapeutic solutions for obesity and sexual health	-	Colt Ventures, Athyrium Capital Management ... & 9 others	57/100
4th	Gossamer Bio 2017, San Diego (United States), Public	Developer of small molecule-based therapies for treating immunological disorders, inflammation, and cancer	$330M	The Baupost Group, Rock Springs Capital & 15 others	58/100
5th	Tenax Therapeutics 1967, Morrisville (United States), Public	Developer of therapeutics to address cardiovascular and pulmonary diseases	-	RTW Investments, Westwicke & 1 others	52/100
6th	Corsair Phama 2014, San Francisco (United States), Series B	Developer of drugs for the treatemnt of cardiac diseases	$23M	New Rhein, Primavera & 3 others	51/100
7th	Aerovate Therapeutics 2018, Boston (United States), Public	Developer of therapeutic solutions for pulmonary arterial hypertension	$75.8M	Sofinnova Investments, Atlas Venture & 1 others	42/100
8th	CoTherix 2000, San Francisco (United States), Acquired	Inhaled therapeutics for the treatment of cardiopulmonary diseases.	$55M	Frazier Life Sciences, Sofinnova Partners ... & 7 others	42/100
9th	tiakis BIOTECH 2000, Kiel (Germany), Series A	Developer of anti-inflammatory and tissue-protective drugs	-	Elevat3 Capital	39/100
10th	Apaxen 2018, Charleroi (Belgium), Series A	Developer of small molecules for treating pulmonary diseases	$3.64M	Theodorus, India Innovation Fund & 1 others	32/100